Xerion appoints internationally renowned oncology expert
PUBLISHED: 14:23 12 April 2018 | UPDATED: 10:35 13 April 2018
Commenting on his appointment, Professor Justin Stebbing, Chairman of Xerion, said: “I am delighted to be joining the board of Xerion at a point when the company’s technology is rapidly advancing into the clinic.”
Oxfordshire based Xerion Healthcare welcomes Professor Justin Stebbing as Chairman to drive the company forward as it looks to progress from pre-clinical to patient trials with the aim of increasing quality and length of life of cancer suffers.
Xerion’s cost-effective nanotechnology is set to make a huge impact by initially targeting head and neck and pancreatic cancers, both of which have unmet clinical needs.
An internationally renowned oncology expert, Professor Stebbing, has published over 600 peer-reviewed papers, is a Fellow of the Royal College of Physicians and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees.
Commenting on his appointment, Professor Justin Stebbing, Chairman of Xerion, said: “I am delighted to be joining the board of Xerion at a point when the company’s technology is rapidly advancing into the clinic. Xerion is a truly unique company and its technology has the potential to change patient care for many difficult to treat solid tumours. I look forward to working with the board and management team to translate Xerion’s technology into effective therapies for cancer patients.”
Dr Ian George, Chief Executive Officer, Xerion Healthcare, said: “Professor Stebbing’s clinical experience and international standing in the field of cancer treatment will be a huge asset for the company. Justin joins the board at a transformational time and his experience will be invaluable in accelerating our clinical pipeline.”
Xerion’s nanoparticles are injected into tumours, dispersing throughout the tumour and into cancer cells. When radiotherapy treatment is applied, the nanoparticles generate highly active molecular species, known as ‘free radicals’, which destroy the tumour cells. The nanoparticles split water, rather than interacting with oxygen, allowing the most aggressive oxygen deficient tumour types to be targeted.
Xerion is an Oxford University spin-out where Professor Stebbing graduated with a first class degree in medicine before completing training in Oxford hospitals.
Xerion was founded in 2015 with investment from New Wave Ventures & Parkwalk Advisors and has since been awarded a grant through Innovate UK’s Biomedical Early Catalyst scheme in addition to its recent funding from OSI. The company is now tackling the challenge of progressing from pre-clinical development to patient trials, which are expected to commence early in 2020.
For further information about Xerion Healthcare, visit the website here.